Reviewed by Michael Gill, B. Sc.
25 Type 1 Diabetes Clinical Trials Near Me
Top Hospitals for Type 1 Diabetes Clinical Trials
Image of University of Minnesota in Minnesota.
University of Minnesota
7Active Trials
46All Time Trials for Type 1 Diabetes
1983First Type 1 Diabetes Trial
Top Cities for Type 1 Diabetes Clinical Trials
Type 1 Diabetes Clinical Trials by Phase of Trial
Phase < 1 Type 1 Diabetes Clinical Trials
4Active Type 1 Diabetes Clinical Trials
4Number of Unique Treatments
3Number of Active Locations
ResveratrolTrial 1-SSRICREONGlucagon-like peptide-1
Type 1 Diabetes Clinical Trials by Age Group
< 18 Type 1 Diabetes Clinical Trials
20Active Type 1 Diabetes Clinical Trials
Group education sessions for parents plus usual diabetes careAfrezzaBacillus Calmette-GuérinOnline Learning ModulesActive arm"MyPlan" - Individualized Structured Eating PlanteplizumabMind-body skills + diabetes education
Top Treatments for Type 1 Diabetes Clinical Trials
Treatment Name
Active Type 1 Diabetes Clinical Trials
All Time Trials for Type 1 Diabetes
First Recorded Type 1 Diabetes Trial
Intraportal infusion of islet cells
Bacillus Calmette-Guérin
t:slim X2 insulin pump with Control-IQ technology 1.5
Recently Completed Studies with FDA Approved Treatments for Type 1 Diabetes
Youngene Therapeutics Inc., Ltd.

What Are Type 1 Diabetes Clinical Trials?

Type 1 Diabetes is a chronic and potentially life-threatening condition wherein a patient's pancreas no longer produces insulin or produces very little. Insulin is used throughout the body to control boog glucose levels, which may cause further medical complications if not kept within a specific range.

When the pancreas no longer produces insulin, patients with Type 1 Diabetes need to regulate their blood sugar levels through various medications and insulin injections. This condition typically affects children, teens, and young adults and is commonly referred to as Juvenile Diabetes. There are currently more than 280,000 adolescents living with this condition in the United States.

Trials for Type 1 Diabetes are an essential cornerstone to understanding and managing this chronic condition. The research and tests undertaken by medical professionals hope to uncover new ways of treating, preventing, and managing the condition. The secondary aim of the trials is to give existing patients a better quality of life and find a cure. There is currently no available cure for Type 1 Diabetes.

Why Is Type 1 Diabetes Being Studied Through Clinical Trials?

Type 1 Diabetes is a debilitating condition that can affect multiple facets of a patient's life. Without proper management, patients can develop severe co-morbidities. In some cases, Type 1 Diabetes has also been linked to multiple deaths.

For this reason, researchers are studying the condition to improve symptom management, prevent the onset of co-morbidities, study the impact of new medications, and test the effectiveness of medical equipment.

Typically, trials are done to test new medications to help existing patients or to prevent the diagnoses of others using preventative drugs.

What Are The Types of Treatments Available For Type 1 Diabetes?

Diabetes is treated with a series of medications, with the primary medication being insulin. New forms of insulin delivery are being tested in Type 1 trials, as well as the accompanying delivery systems such as insulin pumps.

Trials also consist of behavioral therapies, diagnostics, and uncovering new risk factors that may help medical professionals diagnose or pinpoint Type 1 before it is irreversible. There is no current cure for diabetes, meaning researchers are focusing on ways to prevent future diagnoses and reverse the effects on existing patients.

There is also no specific cause for Type 1 Diabetes, and researchers are currently working on narrowing their search for any genetic significance that may help with diagnostic testing.

What Are Some Recent Breakthrough Clinical Trials For Type 1 Diabetes?

With research and understanding about Type 1 Diabetes growing exponentially in recent years, multiple new research findings have surfaced. The most noteworthy findings include the following:

2020: Type 1 Diabetes Screening – A study in Germany found that screening young children between the age of two and five years old reduced the risk of undiagnosed diabetic juveniles developing diabetic ketoacidosis. This serious condition affects people with diabetes with mismanaged blood sugar or undiagnosed diabetes. It can be life-threatening for Type 1 diabetics, particularly children.

2022: Pancreatic Cell Regeneration – Researchers in Melbourne, Australia, at Monash University successfully rehabilitate previously inhibited insulin-producing pancreatic cells (also known as β-cells or beta-cells). This therapy has furthered the cause for a potential cure for Type 1 Diabetes and the hastened reversal of Type 2.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Hear